Replies to post #126967 on Biotech Values

[DewDiligence]

Bloomberg piece says HGSI having the same kinds of reimbursement issues as DNDN:

http://www.bloomberg.com/news/2011-09-29/biotech-investors-bow-out-after-approvals-as-sales-hurdles-grow.html

Maybe the problem with Benlysta (as with Provenge) is that the demand is simply less than what some investors thought.